Child: ≥6 yr 22-31 kg: 600 mg once daily; 32-54 kg: 900 mg once daily; ≥55 kg: 1,200 mg once daily.
Oral Osteoarthritis, Rheumatoid arthritis
Adult: 1,200 mg once daily. Max: 1,800 mg or 26 mg/kg, whichever is lower, given in divided doses.
Special Patient Group
Patient w/ low body wt: Osteoarthritis; Rheumatoid arthritis: Initially, 600 mg once daily.
Osteoarthritis; Rheumatoid arthritis: Severe or on dialysis: Initially, 600 mg once daily, may be increased to 1,200 mg once daily if necessary.
Chống chỉ định
Hypersensitivity. History of bronchospasm, asthma, urticaria, or other allergic-type reactions w/ NSAIDs; active GI bleeding, severe heart failure, recent MI. CABG surgery.
Patient w/ history of peptic ulcer disease and/or GI bleeding, coagulopathy, HTN, oedema, known or risk factors for CV disease, on dialysis, DM, other forms of asthma. Smokers. Severe renal and hepatic impairment. Childn. Pregnancy and lactation.
PO: C (Avoid during 3rd trimester or near delivery)
Thông tin tư vấn bệnh nhân
This drug may cause drowsiness, dizziness and blurred vision, if affected, do not drive or operate machinery.
Monitor BP, CBC, K levels, renal function, and LFT. Monitor signs and symptoms of GI bleeding.
Symptoms: Lethargy, drowsiness, nausea, vomiting, abdominal pain, GI bleeding, HTN, acute renal failure, resp depression, coma. Management: Symptomatic and supportive treatment. May consider emesis and/or activated charcoal admin.
Increased risk of renal toxicity w/ diuretics, ACE inhibitors, angiotensin II receptor blockers (ARBs). Increased risk of bleeding w/ anticoagulants, antiplatelets, SSRIs, serotonin norepinephrine reuptake inhibitors. Increased risk of hyperkalaemia w/ ACE inhibitors. May increase serum conc of lithium. May increase serum concentration and prolong the half-life of digoxin. May increase the risk of methotrexate and ciclosporin toxicity. Increased risk of myelosuppression, renal and GI toxicity w/ pemetrexed. May decrease antihypertensive effect of diuretics, ACE inhibitors, ARBs, β-blockers. May decrease natriuretic effect of furosemide. Potentially Fatal: Increased risk of GI adverse events w/ oral corticosteroids, aspirin, anticoagulants, SSRIs.
Increased risk of GI adverse events w/ alcohol.
False positive result for benzodiazepines in urine immunoassay screening test.
Description: Oxaprozin is a propionic acid derivative NSAID w/ analgesic, and antipyretic properties. It inhibits the enzyme cyclooxygenase-1 and 2 (COX-1 and 2) resulting in the blockage of prostaglandin synthesis. Pharmacokinetics: Absorption: Slowly but extensively absorbed from the GI tract. Time to peak plasma concentration: Approx 2-3 hr. Distribution: Volume of distribution: 11-17 L/70 kg. Plasma protein binding: 99%, mainly to albumin. Metabolism: Metabolised in the liver via oxidation and glucuronidation into ester and ether inactive glucuronide metabolites and active phenolic metabolite (small amount). Excretion: Mainly via urine (5%, as unchanged drug; 65%, as metabolites); faeces (35%, as metabolites). Elimination half-life: 41-55 hr.
M01AE12 - oxaprozin ; Belongs to the class of propionic acid derivatives of non-steroidal antiinflammatory and antirheumatic products.
Anon. Oxaprozin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 13/09/2017.Buckingham R (ed). Oxaprozin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com/. Accessed 19/09/2017.McEvoy GK, Snow EK, Miller J et al (eds). Oxaprozin. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 19/09/2017.Oxaprozin Tablet, Film Coated (PD-Rx Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 19/09/2017.